Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001129928-25-000046
Filing Date
2025-07-08
Accepted
2025-07-08 17:26:57
Documents
12
Period of Report
2025-07-08

Document Format Files

Seq Description Document Type Size
1 6-K a2025informationcircularfo.htm 6-K 19534
2 EX-99.1 onc-micfinal2025.htm EX-99.1 583205
3 EX-99.2 a0772025onco-proxy.htm EX-99.2 9159
4 image_0.jpg GRAPHIC 74787
5 image_1firstpage.jpg GRAPHIC 356318
6 image_31.jpg GRAPHIC 64791
7 image_5.jpg GRAPHIC 263135
8 image_6.jpg GRAPHIC 91994
9 virtualmeetingguide1.jpg GRAPHIC 666873
10 virtualmeetingguide2.jpg GRAPHIC 586431
11 a0772025onco-proxy001.jpg GRAPHIC 247384
12 a0772025onco-proxy002.jpg GRAPHIC 161222
  Complete submission text file 0001129928-25-000046.txt   4072762
Mailing Address 804, 322 - 11 AVENUE SW CALGARY A0 T2R 0C5
Business Address 804, 322 - 11 AVENUE SW CALGARY A0 T2R 0C5 4036707380
ONCOLYTICS BIOTECH INC (Filer) CIK: 0001129928 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-38512 | Film No.: 251111783
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)